Xencor Inc (XNCR) — SEC Financial Statements & Analysis

Xencor Inc (XNCR) is a pharmaceutical preparations company, incorporated in DE. Xencor Inc trades on Nasdaq as: XNCR. Xencor Inc (XNCR)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05. Based on that filing, Xencor Inc carries a market cap of $1.22B, a P/E ratio of -7.48x, a P/B ratio of 2.43x, a P/S ratio of 11.63x, an enterprise value of $1.28B, and an EV/EBITDA multiple of -6.22x. On profitability, it posts an operating margin of -205.84%, a net margin of -155.59%, a Return on Equity (ROE) of -29.07%, a Return on Assets (ROA) of -20.36%, and a Return on Invested Capital (ROIC) of -33.53%. Per share, it reports EPS of $-2.15, diluted EPS of $-2.15, free cash flow per share of $-2.75, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -28.56% year-over-year, net income growth of -3.34% year-over-year, and EPS growth of -5.35% year-over-year. On the balance sheet, it maintains a current ratio of 6.39x, a quick ratio of 6.09x, working capital of $441.35M, a debt-to-equity ratio of 0.44x, a debt ratio of 0.31, an interest coverage ratio of -7.98x, free cash flow of $-208.28M (TTM), and net debt of $60.04M. Figures sourced from SEC EDGAR.

Market Cap

$1.22B

P/E TTM

-7.48x

EPS TTM

$-2.15

P/B TTM

2.43x

ROE TTM

-29.07%

ROA TTM

-20.36%

Debt To Equity

0.44x

Free Cash Flow TTM

$-208.28M

Net Revenue TTM Growth 1Y

-28.56%

Data as of 2026-06-30 · Source: SEC EDGAR